Hormonal Medications for Genitourinary Syndrome of Menopause.
Clin Obstet Gynecol
; 67(1): 68-78, 2024 03 01.
Article
en En
| MEDLINE
| ID: mdl-38032827
Genitourinary syndrome of menopause is a common, under-reported, and undertreated chronic progressive condition requiring long-term treatment. Hypoestrogenism in the urogenital tissues is associated with bothersome dyspareunia, vulvovaginal symptoms, overactive bladder, and frequent urinary tract infections. Vaginal hormone therapies, including vaginal estrogen and intravaginal dehydroepiandrostenedione, are safe and effective and improve symptoms and clinical findings. Systemic hormone therapy treats vulvovaginal atrophy less effectively than vaginal hormone therapies with increased stress and urge urinary incontinence. Oral ospemifene effectively treats vaginal dryness and dyspareunia. Clinicians need to ask about symptoms of genitourinary syndrome of menopause, confirm the diagnosis, and suggest appropriate treatment options.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Dispareunia
Límite:
Female
/
Humans
Idioma:
En
Revista:
Clin Obstet Gynecol
Año:
2024
Tipo del documento:
Article
Pais de publicación:
Estados Unidos